Quent Capital’s Charles River Laboratories CRL Stock Holding History

Quent Capital’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$21.9K	Sell	127 -6	-5%	-$1.11K	﹤0.01%	967
2025 Q4	$26.5K	Sell	133 -12	-8%	-$2.18K	﹤0.01%	920
2025 Q3	$22.7K	Buy	+145	New	+$23K	﹤0.01%	821
2025 Q2	–	Sell	-160	Closed	-$24.1K	–	486
2025 Q1	$24.1K	Buy	160 +4	+3%	+$671	﹤0.01%	726
2024 Q4	$28.8K	Hold	156	–	–	﹤0.01%	718
2024 Q3	$30.7K	Hold	156	–	–	﹤0.01%	782
2024 Q2	$32.2K	Sell	156 -24	-13%	-$5.44K	﹤0.01%	742
2024 Q1	$48.8K	Buy	180 +1	+0.6%	+$239	0.01%	671
2023 Q4	$42.3K	Sell	179 -12	-6%	-$2.36K	0.01%	660
2023 Q3	$37.4K	Sell	191 -13	-6%	-$2.67K	0.01%	659
2023 Q2	$42.9K	Hold	204	–	–	0.01%	626
2023 Q1	$41.2K	Buy	204 +6	+3%	+$1.36K	0.01%	638
2022 Q4	$43.1K	Hold	198	–	–	0.01%	620
2022 Q3	$39K	Buy	198 +44	+29%	+$9.5K	0.01%	608
2022 Q2	$33K	Hold	154	–	–	0.01%	616
2022 Q1	$44K	Buy	154 +38	+33%	+$11.7K	0.01%	630
2021 Q4	$44K	Buy	+116	New	+$45.1K	0.01%	580

Other funds holding CRL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Quent Capital's CRL Position: Q1 2026 in Review

Quent Capital reduced its Charles River Laboratories (CRL) stake by 4.5% in Q1 2026, selling an estimated $1.11K and leaving 127 shares worth $21.9K. The position accounts for ﹤0.01% of the portfolio, ranked #967.

Quent Capital first reported a position in CRL in Q4 2021 and has held it in 17 quarters since. The position peaked at $48.8K in Q1 2024. 558 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

Quent Capital held 127 shares of Charles River Laboratories worth $21.9K as of Q1 2026.
Quent Capital sold 6 Charles River Laboratories shares in Q1 2026, an estimated $1.11K.
Charles River Laboratories made up ﹤0.01% of Quent Capital's portfolio in Q1 2026, its #967 holding.
Quent Capital first reported a position in Charles River Laboratories in Q4 2021 and has held it in 17 quarters since.
Quent Capital's Charles River Laboratories position peaked at $48.8K in Q1 2024.
558 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Quent Capital's 13F filing for Q1 2026, filed 28 Apr 2026.